Abstract 31P
Background
Breast edema is defined as a high signal intensity on T2-weighted magnetic resonance imaging (MRI), and it is an essential image phenotype of breast MRI. The purpose of this study was to investigate the prognostic implication of breast edema on preoperative breast MRI in breast cancer patients.
Methods
We retrospectively analyzed the data of 899 breast cancer patients at a single institution. Patients were divided into the edema-positive group (EPG) and the edema-negative group (ENG) according to the presence of breast edema on preoperative breast MRI. We compared the clinicopathologic characteristics and the survival outcomes between the two groups. A two-sample t-test was used to determine statistical differences between mean ages, and Pearson’s χ2 test was used to determine statistical differences between all the other baseline characteristics. The log-rank test was used to compare the survival curves from Kaplan–Meier estimator. The Cox proportional hazards model was used to calculate the hazard ratio (HR) and 95% confidence interval (CI).
Results
There were 399 (44.4%) patients in the EPG and 500 (55.6%) patients in the ENG. Among patients in the EPG, peritumoral, prepectoral, and subcutaneous edemas were present in 387, 130, and 66 patients, respectively. EPG showed significantly higher rates of axillary lymph node metastasis (55.6% vs. 19.2%, p < 0.001) and lymphovascular invasion (LVI) (57.9% vs. 12.6%, p < 0.001) than ENG. Patients in the EPG showed significantly worse overall survival rate (log-rank p < 0.001; HR: 4.83; 95% CI: 2.56-9.11) and recurrence-free survival rate (log-rank p < 0.001; HR: 3.00; 95% CI: 1.94-4.63) than those in the ENG. After adjusting for other variables, breast edema still remained a significant factor affecting overall survival rate regardless of edema type.
Conclusions
Breast edema on preoperative breast MRI is strongly correlated with several clinicopathological features including nodal metastasis and LVI in breast cancer patients. It significantly affects the survival rate and disease recurrence of breast cancer patients. Therefore, detailed descriptions of breast edema in preoperative breast MRI may provide prognosis prediction and more intensive surveillance is needed for breast cancer patients with breast edema.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract